- Home
- RC vs KALV Comparison
RC vs KALV Comparison
Compare RC & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RC
- KALV
- Stock Information
- Founded
- RC 2007
- KALV N/A
- Country
- RC United States
- KALV United States
- Employees
- RC N/A
- KALV N/A
- Industry
- RC Real Estate Investment Trusts
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- RC Real Estate
- KALV Health Care
- Exchange
- RC Nasdaq
- KALV Nasdaq
- Market Cap
- RC 517.6M
- KALV 551.2M
- IPO Year
- RC N/A
- KALV N/A
- Fundamental
- Price
- RC $2.39
- KALV $13.04
- Analyst Decision
- RC Hold
- KALV Strong Buy
- Analyst Count
- RC 5
- KALV 8
- Target Price
- RC $5.75
- KALV $26.43
- AVG Volume (30 Days)
- RC 2.9M
- KALV 1.4M
- Earning Date
- RC 11-06-2025
- KALV 11-10-2025
- Dividend Yield
- RC 21.46%
- KALV N/A
- EPS Growth
- RC N/A
- KALV N/A
- EPS
- RC N/A
- KALV N/A
- Revenue
- RC N/A
- KALV $1,426,000.00
- Revenue This Year
- RC N/A
- KALV N/A
- Revenue Next Year
- RC $141.93
- KALV $234.65
- P/E Ratio
- RC N/A
- KALV N/A
- Revenue Growth
- RC N/A
- KALV N/A
- 52 Week Low
- RC $2.32
- KALV $7.30
- 52 Week High
- RC $7.64
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- RC 25.65
- KALV 57.38
- Support Level
- RC $2.62
- KALV $10.55
- Resistance Level
- RC $3.05
- KALV $14.97
- Average True Range (ATR)
- RC 0.16
- KALV 0.85
- MACD
- RC -0.02
- KALV 0.22
- Stochastic Oscillator
- RC 8.22
- KALV 60.75
About RC Ready Capital Corproation
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.